Virtual Edinburgh Kilt Walk
11th to 13th of September
This September is Gynaecological Cancer Awareness Month. We’re asking you to Step Up for Ovarian Cancer and join our Virtual Edinburgh Kilt Walk Team from the 11th to 13th of September.
We’ve joined forces with the University of Edinburgh Development Trust to support the leading UK low-grade serous cancer research team at the Edinburgh Cancer Research Centre.
Over the Virtual Weekend get that tartan on and take on any Kiltwalk Inspired challenge you wish from home. Walk, run, cycle – it’s up to you. Be active and raise vital funds for research to find better treatments to help women with ovarian cancer live longer.
Every donation will be matched by up to 50%.
Diane was diagnosed with low-grade serous carcinoma at 49 years old. In the last six years she has had three surgeries, two courses of chemotherapy and several hormone therapy treatments.
As a palliative care nurse specialist she never expected, at the height of her career, to be on the receiving end of palliative care herself.
She continues to tirelessly raise awareness of this disease and to raise money for vital research to find successful treatments with hopefully a cure.
“As long as I’m alive I will fight as hard as I can for research to save other young women from dying with ovarian cancer. Please Step Up and fundraise for research.”
Supporting the search for better treatments
All funds raised for Low Grade Serous Ovarian Cancer (LGSOC) research in the UK are being directed to the Edinburgh Cancer Research Centre, part of the University of Edinburgh, to support Professor Charlie Gourley and his team who are focussed on understanding the genetic and genomic origins of low-grade serous ovarian cancer, and, how this information can be used to better detect and treat this disease.
Our overall target is to raise £25,000 which will be used to part fund a new position for a LGSOC dedicated researcher to join Professor Gourley’s team. This researchers main objective will be to develop LGSOC organoids, which are a more accurate human tumour model compared to current simple 2D cell cultures.
With these LGSOC organoids in place, we could then improve the testing of new combinations of currently available drugs, new drugs that are discovered via our ongoing drug screening project (currently we are screening 1800 potential drugs) and also further test new drugs published by other LGSOC researchers from across the globe. Together we hope to identify the next candidate drugs, or drug combinations, that will form the basis of our next clinical trials and then will become new and improved treatments for LGSOC.